FDA Expected to Approve Surrogate End Point for Neoadjuvant Breast Cancer Trials

TON - July 2013 Vol 6 No 6 published on July 29, 2013 in FDA Approvals
Caroline Helwick

For years, the cancer research community has pushed for the use of surrogate end points in clinical trials as a means of hastening the drug approval process. These efforts will soon bear fruit, with the release by the US Food and Drug Administration (FDA) of its final guidance for accelerated drug approval in the neoadjuvant breast cancer treatment setting. At the 2013 American Society of Clinical Oncology Annual Meeting, the speakers discussed the potential implications for researchers, providers, and patients.

Under the new guidance for the pharmaceutical industry, accelerated approval could be granted based on a surrogate end point that predicts clinical benefit; accelerated approval would require subsequent confirmation in a clinical trial.

For neoadjuvant breast cancer, this end point would likely be pathologic complete response (pCR) rate. The achievement of a pCR has been associated with superior outcomes in multiple studies, but the correlation needs further validation, said Tatiana M. Prowell, MD, medical officer for the Breast Oncology Group at the FDA, and assistant professor at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

While pCR will most likely be the surrogate end point, other outcomes have been studied in patients with breast cancer, including tumor response on imaging, measurement of the tumor proliferation marker Ki-67, preoperative endocrine prognostic index (PEPI), and residual cancer burden after treatment.

Faster Approval of Drugs to Most Benefit High-Risk Patients

The traditional drug approval process averages 10 to 15 years. The goal of accelerated approval is to provide early access to effective drugs and to provide incentives for developing drugs for particular breast cancer subtypes with unmet needs.

Under the new approval process, a single trial or a short-duration trial would be appropriate for accelerated approval and a simultaneous longer trial would be conducted to support “regular” approval, according to speakers at the “Pushing the Limits of Upfront Care and Drug Development: Neoadjuvant Opportunities in Breast Cancer” session.

The use of pCR to support accelerated approval is appropriate “for highly promising drugs and high-risk patient populations,” Prowell maintained.

Session Chair Angela DeMichele, MD, of the Abramson Cancer Center of the University of Pennsylvania, Philadelphia, noted there is a “fertile environment” for new drug development in the neoadjuvant breast cancer treatment setting, as the many benefits of neoadjuvant therapy are now established.

Moving clinical trials from the adjuvant to the neoadjuvant setting can yield important information about the drugs that are under evaluation, such as the ability of pharmacodynamic markers to provide in vivo evidence of biologic effects. But most importantly, they should identify active agents faster, which serves patients, DeMichele said.
She emphasized that surrogate markers must be robust, ie, reproducible and standardized, and their correlation with the true end point (such as overall survival) must be more than a simple “correlation.” In this case, pCR must be strictly defined as the elimination of all invasive and noninvasive disease in the breast and lymph nodes, rather than a “looser” definition. Its relationship with the final end point can be assured only through long-term follow-up of patients, she added.

DeMichele also proposed that pCR may not be a valid surrogate end point for every breast cancer. While it may be appropriate for human epidermal growth factor receptor 2 (HER2)-positive, triple-negative, and highly proliferative estrogen receptor (ER)-positive disease, it may not be a good surrogate for low-proliferation ER-positive tumors. At present, she believes Ki-67 is the best surrogate for the latter, though it is not perfect. Better surrogates are needed for this subset, she said.

Reference
DeMichele A. Pushing the limits of upfront care and drug development: neoadjuvant opportunities in breast cancer. Presented at: 2013 Annual Meeting of the American Society of Clinical Oncology; June 1, 2013; Chicago, IL. Education Session.

Related Items
Keytruda Approved for Patients with Previously Treated Metastatic Small-Cell Lung Cancer
Yvette Florio Lane
Web Exclusives published on June 26, 2019 in FDA Approvals, In the News
First Chemoimmunotherapy Regimen Granted Accelerated Approval for Patients with Previously Treated DLBCL
Yvette Florio Lane
Web Exclusives published on June 12, 2019 in FDA Approvals, In the News
Welcome to the Fourth Annual Oncology Guide to New FDA Approvals
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Approvals
New Indications Approved by the FDA in 2018 for Oncology Drugs
Dalia Buffery, MA, ABD
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Approvals
FDA Approvals of Novel Brand-Name Prescription Cancer Drugs in 2018
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Approvals
Braftovi (Encorafenib) plus Mektovi (Binimetinib) Third BRAF/MEK Inhibition Combination Approved for Metastatic Melanoma with BRAF Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Approvals, Melanoma
Copiktra (Duvelisib) Approved for Relapsed or Refractory CLL, SLL, and Follicular Lymphoma
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Approvals, Lymphoma
Daurismo (Glasdegib) Approved, in Combination with Low-Dose Cytarabine, for Newly Diagnosed Acute Myeloid Leukemia in Older Adults or Those Unfit for Intensive Chemotherapy
Loretta Fala, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Approvals, Leukemia
Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer
Loretta Fala, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Approvals, Prostate Cancer
Imbruvica (Ibrutinib) plus Rituxan (Rituximab) New Combination Approved for the Treatment of Waldenström’s Macroglobulinemia
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Approvals, Lymphoma
Last modified: July 28, 2015